Leerink Partnrs Brokers Lower Earnings Estimates for Geron

Geron Co. (NASDAQ:GERN) – Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Geron in a note issued to investors on Monday, January 6th. Leerink Partnrs analyst F. Khurshid now expects that the biopharmaceutical company will post earnings per share of $0.00 for the quarter, down from their prior forecast of $0.01. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron’s Q3 2025 earnings at $0.01 EPS and Q4 2025 earnings at $0.02 EPS.

A number of other analysts have also issued reports on the company. Leerink Partners assumed coverage on Geron in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target on the stock. Barclays raised shares of Geron to a “strong-buy” rating in a report on Friday, November 29th. Scotiabank began coverage on shares of Geron in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Geron in a research note on Tuesday, December 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of Geron in a report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Geron presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.15.

Geron Trading Down 3.9 %

GERN stock opened at $3.43 on Tuesday. Geron has a 12-month low of $1.64 and a 12-month high of $5.34. The business’s 50-day moving average is $3.87 and its 200 day moving average is $4.26. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -10.72 and a beta of 0.51.

Geron (NASDAQ:GERN) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.05. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The business had revenue of $28.27 million for the quarter, compared to analyst estimates of $18.97 million. During the same quarter last year, the business earned ($0.08) earnings per share. The company’s revenue for the quarter was up 17138.4% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GERN. National Bank of Canada FI lifted its stake in shares of Geron by 1,200.0% in the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 6,000 shares during the last quarter. Readystate Asset Management LP purchased a new stake in Geron in the 3rd quarter valued at about $58,000. Rovin Capital UT ADV acquired a new position in Geron in the third quarter valued at about $62,000. CIBC Asset Management Inc boosted its stake in Geron by 32.7% during the second quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 3,805 shares during the period. Finally, Empowered Funds LLC acquired a new stake in shares of Geron during the third quarter valued at about $67,000. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.